logo-loader

MagicMed Industries and Enveric Biosciences finalize merger creating new psychedelic drug discovery company

Published: 09:33 17 Sep 2021 EDT

Enveric Biosciences -
Following the deal, existing Enveric shareholders own around 68.3% of the combined company's stock and previous MagicMed shareholders own about 31.7%

Enveric Biosciences (NASDAQ:ENVB, FRA:SLZ) Inc announced it has closed the acquisition of MagicMed Industries Inc, a Canadian biotechnology firm with a library of novel derivative psychedelics molecules known as the Psybrary. 

The all-stock transaction sees MagicMed’s CEO Joseph Tucker taking on the CEO role at Enveric, with former Enveric CEO David Johnson becoming executive chairman. 

Under the term sheet to acquire privately-held MagicMed, Enveric issued MagicMed shareholders an aggregate of 9,951,237 Enveric shares. 

READ: MagicMed bidder Enveric Biosciences issues letter to shareholders ahead of merger

Following the deal, existing Enveric shareholders own around 68.3% of the combined company's stock and previous MagicMed shareholders own around 31.7%.

Enveric also received about C$4 million in cash from MagicMed as part of the closing of the transaction.

In a statement, Enveric told investors that the firm plans to “immediately accelerate” the development of a novel psychedelic molecule for cancer-related distress.

"Enveric is a biotechnology company with the platform to create intellectual property for the next generation of mental health treatments to fight a global crisis,” Tucker said.

“With both psychedelic derived molecules and cannabinoids, we have a robust pipeline to take us from discovery through clinical development. Our platform has the potential to disrupt and unlock much-needed mental health treatments through psychedelic therapies.”

Johnson added: “From the onset of meeting Dr. Tucker and the MagicMed team, I have been impressed by what they have accomplished, most notably their library of intellectual property for next-generation psychedelic molecules. These assets combined with our existing Enveric pipeline opens the door for multiple treatment opportunities to a large patient population.”

Enveric is a Naples, Florida-based biotechnology company focused on mental health and cancer treatment.

Contact Angela at angela@proactiveinvestors.com

Follow her on Twitter @AHarmantas

MagicMed and Proactive Present Magic Moments Videocast on AI in Psychedelics

Dr. Joseph Tucker, CEO of MagicMed and Steve Darling, Senior Broadcaster from Proactive talk about the use of Artificial Intelligence in the Psychedelpics sector with special guests Richard Dallaway, Founder of April19, and Roshan Bhave, Senior Data Scientist for Cognistx.

on 03/18/2021